Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome
N/A
N/A
Both
Neuroblastoma
Trial Information
Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome
To collect tumor, marrow specimens prospectively to study the molecular-genetic makeup of
individual neuroblastic tumor and its metastasis by blood and marrow, and to correlate these
findings with clinical outcome, and to relate the signaling circuitry of neuroblastic tumors
to that of embryonic neuroectodermal cells. .
Inclusion Criteria:
- Neuroblastic tumors diagnosed in accordance with the International Neuroblastoma
Staging System viz., either (a) histologic confirmation (by the MSKCC Department of
Pathology) which may involve immunohistochemical, ultrastructural, or cytogenetic
studies, or (b) elevated urinary catecholamines plus tumor cells/clumps in the bone
marrow.
OR
- Clinically suspected neuroblastic tumors prior to diagnostic surgery.
Exclusion Criteria:
- None
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
To study the molecular-genetic makeup and metastasis of neuroblastic tumors.
Outcome Time Frame:
Before surgery and a maximum of 10 times
Safety Issue:
No
Principal Investigator
Nai-Kong Cheung, M.D., Ph.D.
Investigator Role:
Principal Investigator
Investigator Affiliation:
Memorial Sloan-Kettering Cancer Center
Authority:
United States: Institutional Review Board
Study ID:
00-109
NCT ID:
NCT00588068
Start Date:
September 2000
Completion Date:
September 2013
Related Keywords:
- Neuroblastoma
- Adrenal Gland
- No stage requirement
- Neuroblastoma
Name | Location |
|---|---|
| Memorial Sloan-Kettering Cancer Center | New York, New York 10021 |
